This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Akili Croissance future

Future contrôle des critères 2/6

Akili is forecast to grow revenue at 44.2% per annum.

Informations clés

n/a

Taux de croissance des bénéfices

n/a

Taux de croissance du BPA

Healthcare Services croissance des bénéfices	0%
Taux de croissance des recettes	44.2%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	21 Jun 2024

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Prévisions de croissance des bénéfices et des revenus

BMV:AKLI * - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	9	N/A	N/A	N/A	1
12/31/2025	6	N/A	N/A	N/A	1
12/31/2024	4	N/A	N/A	N/A	1
3/31/2024	2	-49	-49	-49	N/A
12/31/2023	2	-59	-58	-58	N/A
9/30/2023	1	-65	-70	-70	N/A
6/30/2023	0	2	-73	-73	N/A
3/31/2023	0	-14	-80	-80	N/A
12/31/2022	0	-19	-84	-84	N/A
9/30/2022	0	-26	-81	-81	N/A
6/30/2022	0	-99	-75	-74	N/A
3/31/2022	0	-144	-68	-67	N/A
12/31/2021	1	-127	-54	-54	N/A
9/30/2021	0	-111	-43	-42	N/A
12/31/2020	4	-26	-25	-25	N/A
12/31/2019	20	-21	-30	-29	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Insufficient data to determine if AKLI *'s forecast earnings growth is above the savings rate (7.8%).

Bénéfices vs marché: Insufficient data to determine if AKLI *'s earnings are forecast to grow faster than the MX market

Croissance élevée des bénéfices: Insufficient data to determine if AKLI *'s earnings are expected to grow significantly over the next 3 years.

Chiffre d'affaires vs marché: AKLI *'s revenue (44.2% per year) is forecast to grow faster than the MX market (6.9% per year).

Croissance élevée des revenus: AKLI *'s revenue (44.2% per year) is forecast to grow faster than 20% per year.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Insufficient data to determine if AKLI *'s Return on Equity is forecast to be high in 3 years time

This company listing is no longer active

Akili Croissance future

Future contrôle des critères 2/6

Informations clés

Mises à jour récentes de la croissance future

Recent updates

Akili, Inc.(NasdaqCM:AKLI) dropped from NASDAQ Composite Index

Akili to Delist from Nasdaq

Akili Announces FDA Authorization of EndeavorOTC, the First FDA Clearance of a Digital Treatment for Adults with AdHD Through a Video Game

Virtual Therapeutics Corp. entered into an agreement to acquire Akili, Inc. (NasdaqCM:AKLI) for $35 million.

Virtual Therapeutics Corp. entered into an agreement to acquire Akili, Inc. (NasdaqCM:AKLI) for $35 million.

Akili, Inc. to Reduce Workforce

Akili, Inc. Plans to Continue to Pursue Marketing Authorization from the U.S. Food and Drug Administration for Its EndeavorOTC Product

Akili, Inc. Receives A Letter from the Listing Qualifications Staff of the Nasdaq Stock Market LLC

Full year 2023 earnings released: US$0.76 loss per share (vs US$0.64 loss in FY 2022)

High number of new and inexperienced directors

Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's Endeavorrx®? for Pediatric Adhd Patients in Japan

Akili, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Akili, Inc. Announces Resignation of Santosh Shanbhag as Chief Financial Officer, Effective on January 12, 2024

Akili Receives Non-Compliance Notice from Nasdaq

Akili, Inc. Announces Kenneth Ehlert Resigns as A Member of the Board of Director, Member of the Audit Committee and Nominating and Corporate Governance Committee of the Board

Akili, Inc. Receives Authorization from the U.S. Food and Drug Administration

Akili Receives Non-Compliance Notice from Nasdaq

Akili, Inc. Releases Results from A New Study Examining the Way in Which Adhd Impacting the U.S. Workforce

Akili, Inc. Announces CEO Changes

Akili Releases EndeavorOTC on Android Devices, Expanding Treatment Access for Millions of Adults with Adhd

High number of new and inexperienced directors

Akili Releases EndeavorOTC Video Game Treatment to Improve Attention in Adults with Adad

Akili, Inc. to Present Clinical Data from Pivotal Trial of Video Game Treatment in Adolescents with Adolescents At 2023

First quarter 2023 earnings released: US$0.27 loss per share (vs US$17.96 loss in 1Q 2022)

High number of new and inexperienced directors

High number of new and inexperienced directors

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance